We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

96 hedge funds and large institutions have $172M invested in Rigel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 41 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $153M → $172M (+$19.7M)

8% less funds holding

Funds holding: 104 → 96 (-8)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

44% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 41

Holders
96
Holders Change
-8
Holders Change %
-7.69%
% of All Funds
2.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
23
Reduced
41
Closed
18
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$2K

Top Buyers

1
BC
Broadfin Capital
New York
+$5.06M
2
DCM
DAFNA Capital Management
California
+$1.51M
3
California Public Employees Retirement System
California Public Employees Retirement System
California
+$1.16M
4
Marshall Wace
Marshall Wace
United Kingdom
+$735K
5
OAM
Oxford Asset Management
United Kingdom
+$376K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$2.2M
2
BFA
BlackRock Fund Advisors
California
-$1.55M
3
TC
TFS Capital
Pennsylvania
-$1.54M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.48M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
76
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$43K +$38.6K +1,910 New
ProShare Advisors
77
ProShare Advisors
Maryland
$42K -$124K -6,119 -77%
Barclays
78
Barclays
United Kingdom
$40K -$56.2K -2,777 -58%
Legal & General Group
79
Legal & General Group
United Kingdom
$40K – – –
PNC Financial Services Group
80
PNC Financial Services Group
Pennsylvania
$40K – – –
Citigroup
81
Citigroup
New York
$40K +$29.3K +1,448 +476%
BJ
82
BlackRock Japan
Japan
$37K -$2.81K -139 -8%
AG
83
Algert Global
California
$30K – – –
GC
84
Guggenheim Capital
Illinois
$25K +$22.3K +1,104 New
HighTower Advisors
85
HighTower Advisors
Illinois
$23K – – –
Wells Fargo
86
Wells Fargo
California
$10K +$61 +3 +0.7%
BlackRock
87
BlackRock
New York
$5K -$1.46K -72 -25%
CAW
88
Cornerstone Advisors (Washington)
Washington
$3K -$2.39K -118 -50%
Bank of America
89
Bank of America
North Carolina
$1K -$128K -6,347 -99%
Royal Bank of Canada
90
Royal Bank of Canada
Ontario, Canada
$1K – – –
Manulife (Manufacturers Life Insurance)
91
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$141 +$6.31K +312 +5%
Adage Capital Partners
92
Adage Capital Partners
Massachusetts
– -$1.16M -60,000 Closed
DCM
93
Driehaus Capital Management
Illinois
– -$842K -43,377 Closed
Swiss National Bank
94
Swiss National Bank
Switzerland
– -$178K -9,160 Closed
Jane Street
95
Jane Street
New York
– -$91K -4,713 Closed
SG Americas Securities
96
SG Americas Securities
New York
– -$68K -3,522 Closed
Allianz Asset Management
97
Allianz Asset Management
Germany
– -$68K -3,500 Closed
CI
98
Cowen Inc
New York
– -$70.8K -3,500 -19%
Principal Financial Group
99
Principal Financial Group
Iowa
– -$57K -2,941 Closed
SCM
100
Stevens Capital Management
Pennsylvania
– -$52K -2,694 Closed
1 2 3
4
5

RIGL Hedge Fund Activity: Q4 2014 in Review

96 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2014, worth a combined $172M — up 13% from $153M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of RIGL and 12 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 23 added.

The largest buyer was Broadfin Capital, adding an estimated $5.06M. The largest seller was Millennium Management, cutting an estimated $2.2M.

  • 96 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2014, down from 104 in Q3 2014.
  • Funds reported $172M of Rigel Pharmaceuticals stock for Q4 2014, up 13% quarter-over-quarter.
  • 12 funds opened new Rigel Pharmaceuticals positions in Q4 2014 and 18 closed out, a net change of -6 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2014 was Broadfin Capital, an estimated $5.06M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2014 was Millennium Management, an estimated $2.2M sold.

Based on aggregated 13F filings for Q4 2014.